BioUtah News
-
CenExel Creates Clinical Sciences Business Unit
CenExel announces a new Clinical Sciencesbusiness unit and more.
-
BioHive Summit Recap
On Thursday, November 10, 2022, the BioHIve gathered at the Salt Palace for the annual BioHive Summit presented…
-
Betty Iverson Retirement
Betty Iverson Retirement Announced
-
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.
-
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer…
-
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Clene announced that it has entered into a securities purchase agreement with certain existing stockholders.
-
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24…
-
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal products.
-
Myriad Genetics Reports Third Quarter Financial Results
Myriad Genetics announced financial results for its third quarter ended September 30, 2022 and provided an update on…
-
Renalytix Reports Full Year Fiscal 2022 Results
Renalytix announced its full year results for the twelve months ended 30 June 2022.
-
Merit Medical Reports Results for Quarter Ended September 30, 2022
Merit Medical Systems announced revenue of $287.2 million for the quarter ended September 30, 2022.
-
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
